Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Rare Disease

AstraZeneca ups rare disease research in Canada

by Rick Mullin
March 4, 2023 | A version of this story appeared in Volume 101, Issue 8

 

AstraZeneca plans to add 500 research jobs at its R&D center in Mississauga, Ontario. The UK drugmaker has also announced the formation of a rare disease development hub at the Mississauga center. It obtained its rare disease business with the $39 billion acquisition of the biopharmaceutical firm Alexion in 2020. The center currently leads more than 120 clinical studies in oncology and other disease areas, and it has doubled in size since 2019.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.